Evogene Ltd. (EVGN) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$0.41

From 52W high−70.07%

Volume32381.00

Market cap$6.20M

P/E (TTM)—

P/S (TTM)4.7x

Div yield—

Key dataOct 16, 2026

Open

$0.41

From 52W high

−70.07%

Volume

32381.00

Market cap

$6.20M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

40.6

MomentumView details →

1D Return

−1.95%

YTD Return

−64.53%

SummaryUpdated Jun 1, 2026

Evogene Ltd. (NASDAQ:EVGN) is an Israeli computational biology company founded in 1999 and headquartered in Rehovot, Israel. The company went public in 2010 and operates as a technology-driven life sciences platform that uses artificial intelligence and big data to discover and develop products across agriculture, human health, and industrial applications. Evogene has evolved from a traditional biotechnology company into a computational biology pioneer, leveraging its proprietary Computational Predictive Biology (CPB) platform to create multiple subsidiary companies targeting specific market segments.

Ask drillr about Evogene Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

6.1x

P/S (TTM)

4.7x

P/B (TTM)

−1.9x

ProfitabilityView details →

Gross Margin

−123.87%

Net Margin

−694.19%

EBITDA Margin

−961.36%

ROE (TTM)

275.78%

ROA (TTM)

−67.51%

Asset Turnover

0.08x

GrowthView details →

Revenue YoY

−80.43%

EPS YoY

+59.51%

FCF YoY

+36.55%

Revenue CAGR 3Y

+32.01%

EPS CAGR 3Y

+62.63%

EBITDA YoY

−67.71%

MomentumView details →

1D Return

−1.95%

YTD Return

−64.53%

1Y Return

−68.78%

RSI (14)

40.6

vs 50D SMA

−21.44%

vs 200D SMA

−44.29%

Capital & dividendView details →

Debt/Equity

−0.64x

Current Ratio

3.57x

Quick Ratio

3.54x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

51.85%

Beats (12Q)

5/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

−56.05%

Rev Surprise

8.17%

Financials snapshotView financials →

Revenue (TTM)

1.31M

Net Income (TTM)

−9.07M

Op. CF (TTM)

−11.54M

Next earningsNov 19, 2026 →

Latest newsMore news →

Nasdaq granted Evogene Ltd. an additional 180-day period to regain compliance with the minimum bid price requirement.16d ago

Evogene Ltd. responded to dissident shareholders, urging shareholders to vote for its nominees at the upcoming Annual General Meeting on September 4, 2026.46d ago

Similar companies

Enveric Biosciences, Inc.ENVB Medicus Pharma Ltd. Common StockMDCX Alzamend Neuro, Inc.ALZN Reviva Pharmaceuticals Holdings, Inc.RVPH Acurx Pharmaceuticals, Inc.ACXP Traws Pharma, Inc.TRAW Find similar companies →

Latest newsMore news →

Nasdaq granted Evogene Ltd. an additional 180-day period to regain compliance with the minimum bid price requirement.16d ago Evogene Ltd. responded to dissident shareholders, urging shareholders to vote for its nominees at the upcoming Annual General Meeting on September 4, 2026.46d ago